UK markets closed
NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.55 -1.08 (-1.31%) GOLD FUTURES
2,297.30 -60.40 (-2.56%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,164.76 -2,202.17 (-4.37%)
Syndax Pharmaceuticals, Inc. (SNDX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 21.28 |
| Open | 20.75 |
| Bid | 21.07 x 100 |
| Ask | 21.16 x 200 |
| Day's range | 20.55 - 21.32 |
| 52-week range | 11.22 - 25.34 |
| Volume | |
| Avg. volume | 1,085,069 |
| Market cap | 1.796B |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
- Simply Wall St.
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Insider Monkey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99. Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone. […]
© 2024 Yahoo. All rights reserved.